(Q35624606)

9 August 2017

1 reference

title

An update on bisphosphonates (English)

1 reference

9 August 2017

1

Stanley B Cohen

1 reference

9 August 2017

1 February 2004

1 reference

Current Rheumatology Reports

9 August 2017

1 reference

9 August 2017

6

1 reference

9 August 2017

1

1 reference

9 August 2017

59-65

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-004-0084-2

9 August 2017

0 references

cites work

Intermittent cyclic tiludronate in the treatment of osteoporosis

1 reference

12 December 2020

Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

Joint structure modification in osteoarthritis: development of SMOAD drugs

1 reference

12 December 2020

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

1 reference

12 December 2020

Clodronate and osteoporosis

1 reference

12 December 2020

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

12 December 2020

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

1 reference

12 December 2020

Alendronate for the Treatment of Osteoporosis in Men

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial

1 reference

12 December 2020

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

12 December 2020

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis

1 reference

12 December 2020

Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles

1 reference

12 December 2020

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

12 December 2020

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

1 reference

12 December 2020

Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

12 December 2020

Cyclical pamidronate infusions in postmenopausal osteoporosis.

1 reference

12 December 2020

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

12 December 2020

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate

1 reference

12 December 2020

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

1 reference

12 December 2020

What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates

1 reference

12 December 2020

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

10.1007/S11926-004-0084-2

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14713403